Bioventus (BVS) Operating Income (2020 - 2026)

Bioventus (BVS) has reported Operating Income for 7 consecutive years, with $19.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Income rose 4.13% year-over-year to $19.1 million; the trailing twelve-month figure through Jun 2026 stood at $58.3 million (up 68.51% YoY), and the FY2025 full-year result was $54.0 million, up 455.22% from the prior year.
• Operating Income grew to $19.1 million in Q2 2026 per BVS's latest filing, from $8.4 million in the prior quarter.
• Across five years, Operating Income topped out at $19.5 million in Q4 2025 and bottomed at -$126.8 million in Q4 2022.
• Historically, Operating Income has averaged -$10.1 million across 5 years, with a median of $4.3 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Operating Income tumbled 12014.52% in 2022, then surged 561.2% in 2024.
• Over 5 years, Operating Income stood at -$15.6 million in 2022, then soared by 107.45% to $1.2 million in 2023, then soared by 561.2% to $7.7 million in 2024, then jumped by 152.97% to $19.5 million in 2025, then declined by 1.84% to $19.1 million in 2026.
• According to Business Quant data, Operating Income over the past three periods registered $19.1 million, $8.4 million, and $19.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.